Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03777059 · ClinicalTrials.gov registry record · Phase 3
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 910
- Enrollment target
NCT03777059 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 910 participants.
The verdict
NCT03777059, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 910 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Interventions
- DRUG Placebo
- DRUG Atogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 910 participants |
| Start Date | 2018-12-14 |
| Est. Completion | 2020-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03777059
The ClinicalTrials.gov registry entry for NCT03777059 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 910 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03777059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03777059 about?
NCT03777059 is a clinical study titled "12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine". To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
What is the current status of trial NCT03777059?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 910 participants. The study started on 2018-12-14. Estimated completion is 2020-06-19.
What interventions are being tested in trial NCT03777059?
The interventions under investigation include: Placebo (DRUG), Atogepant (DRUG).
Who is sponsoring clinical trial NCT03777059?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.